Viral infections linked to reduced survival among women with Ovarian Cancer
In a groundbreaking study, scientists have delved into the intricate relationship between infectious agents and the outcomes of high-grade serous epithelial ovarian cancer, a crucial but poorly understood aspect of the disease. The study revealed a significant association between the presence of viruses of interest (VOI) and lower overall survival, shedding light on potential implications for the clinical management of ovarian cancer. The study results were published in the journal PLOS One.
Early 20th-century findings established a link between infectious agents and cancer. Presently, 11 agents are recognized as carcinogenic. About 16% of global cancer cases may be linked to viruses, including HPV in ovarian tumors. The association's significance in high-grade serous ovarian cancer was explored in a single-institution cohort. Hence, in a quest to understand and shed light on the link between infectious agents and ovarian cancer, employing a comprehensive analysis of viral DNA in primary ovarian cancer tumors and its correlation with clinical outcomes was carried out through a cohort study.
Unveiling the Viral Landscape, Researchers meticulously examined archived tumors from 98 patients diagnosed with high-grade serous epithelial ovarian cancer, spanning from January 1, 1994, to December 31, 2010. Leveraging advanced Luminex technology, they identified polymerase chain reaction-amplified viral DNA for a diverse set of 113 specific viruses. Statistical methods, including logistic regression and Cox proportional hazards models, were applied to assess the associations between tumor viral status, disease outcome, and overall survival (OS).
Results:
Viruses of Interest: The findings revealed that almost half of the cases (45.9%) contained at least one virus. Six highly prevalent viruses, designated as viruses of interest (VOI), emerged as key players linked to clinical outcomes. These included Epstein-Barr virus 1, Merkel cell polyomavirus, human herpes virus 6b, and human papillomaviruses 4, 16, and 23.
Overall Survival rates: Significantly, the presence of VOI and platinum sensitivity were independently associated with OS. The median OS was notably reduced in tumors exhibiting VOI compared to those without (22 vs. 44 months). Distinctly, women below 70 years old with VOI in tumors displayed significantly lower median OS compared to age-matched counterparts without VOI (20 vs. 57 months). However, among women aged 70 or older, there was no discernible difference in OS based on tumor virus status.
Thus, the study's groundbreaking findings underscore a significant association between the presence of viruses of interest and lower overall survival in ovarian cancer patients. This revelation holds promise for potential implications in the clinical management of ovarian cancer. However, researchers emphasize the need for additional studies to comprehensively validate and understand the broader implications of these findings in the realm of ovarian cancer treatment. As the scientific community unravels the viral connection, these insights may pave the way for novel approaches to enhance outcomes and refine strategies for managing this complex disease.
Further reading: Prevalence of viral DNA in high-grade serous epithelial ovarian cancer and correlation with clinical outcomes. https://doi.org/10.1371/journal.pone.0294448
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.